Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR – Get Free Report) has received an average rating of “Hold” from the five analysts that are currently covering the firm, MarketBeat reports. One equities research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and three have assigned a buy recommendation to the company. The average 12-month price objective among analysts that have covered the stock in the last year is $39.67.
A number of research analysts have issued reports on PHAR shares. Wall Street Zen upgraded Pharming Group from a “hold” rating to a “strong-buy” rating in a research note on Sunday. Zacks Research raised Pharming Group from a “strong sell” rating to a “hold” rating in a research note on Friday, October 23rd. Weiss Ratings raised Pharming Group from a “sell (d)” rating to a “sell (d+)” rating in a research note on Tuesday. HC Wainwright restated a “buy” rating and set a $37.00 price target on shares of Pharming Group in a report on Tuesday, September 22nd. Finally, Oppenheimer reaffirmed an “outperform” rating on shares of Pharming Group in a research report on Wednesday.
Check Out Our Latest Stock Analysis on Pharming Group
Pharming Group Price Performance
PHAR stock opened at $12.23 on Tuesday. The company has a debt-to-equity ratio of 0.32, a quick ratio of 2.31 and a current ratio of 3.23. The firm has a 50 day moving average price of $10.71 and a 200-day moving average price of $13.80. Pharming Group has a 52-week low of $9.11 and a 52-week high of $21.34. The firm has a market capitalization of $865.64 million, a price-to-earnings ratio of 38.22 and a beta of -0.05.
Pharming Group (NASDAQ:PHAR – Get Free Report) last posted its quarterly earnings results on Tuesday, October 27th. The company reported $0.30 earnings per share for the quarter, topping the consensus estimate of $0.21 by $0.09. Pharming Group had a return on equity of 8.70% and a net margin of 6.23%. The company had revenue of $117.60 million for the quarter, compared to the consensus estimate of $117.60 million. Equities research analysts forecast that Pharming Group will post 0.34 EPS for the current fiscal year.
Institutional Trading of Pharming Group
An institutional investor recently bought a new stake in Pharming Group stock. MAC Alpha Capital Management LP acquired a new stake in shares of Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR – Free Report) in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 2,148,144 shares of the company’s stock, valued at approximately $29,838,000. Pharming Group makes up 6.0% of MAC Alpha Capital Management LP’s investment portfolio, making the stock its 2nd biggest holding. MAC Alpha Capital Management LP owned 3.03% of Pharming Group at the end of the most recent quarter. 0.03% of the stock is owned by institutional investors.
Pharming Group Company Profile
Pharming Group N.V. is a biopharmaceutical company headquartered in Leiden, the Netherlands. The company develops and commercializes medicines for rare diseases and operates internationally, serving patients and healthcare providers in North America, Europe and other selected markets.
Pharming’s principal product is Ruconest, a recombinant C1 esterase inhibitor used to treat acute attacks of hereditary angioedema, a rare genetic disorder that can cause potentially serious swelling. The company also markets Joenja (leniolisib), an oral treatment for activated phosphoinositide 3-kinase delta syndrome (APDS), a rare primary immunodeficiency.
Featured Stories
- Five stocks we like better than Pharming Group
- Starbucks Says Its Turnaround Is Done—The Numbers Make a Strong Case (With 1 Catch)
- 3 Robotics ETFs, 3 Different Ways to Bet on Humanoid Robots
- Can Microsoft Turn a Leaner Workforce and Record AI Spending Into Bigger Profits?
- Why JFrog Could Be the Software Infrastructure Company to Beat in the AI Boom
Receive News & Ratings for Pharming Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pharming Group and related companies with MarketBeat.com's FREE daily email newsletter.
